Most Read Articles
Stephen Padilla, 04 Sep 2019
Use of sodium glucose cotransporter 2 (SGLT2), as compared with dipeptidyl peptidase 4 (DPP4), inhibitors appears to reduce the risk of heart failure and any-cause death without major cardiovascular events in the primary intention-to-treat analysis, according to a study.
Pearl Toh, 04 Sep 2019
More intensive LDL-lowering by adding ezetimibe to simvastatin in elderly individuals aged ≥75 years significantly reduced recurrent cardiovascular (CV) events without raising safety issues compared with simvastatin alone, a secondary analysis of the IMPROVE-IT* has shown.
27 Aug 2019
A once-weekly regimen of 25 mg trelagliptin is effective and safe for type 2 diabetes mellitus (T2DM) patients with severe renal impairment or end-stage renal disease, reports a new study.
Elvira Manzano, 2 days ago

The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.

Susceptibility-guided and empiric therapy equally effective in H. pylori infection

22 May 2019

Susceptibility‐guided therapy is as effective as empiric modified bismuth quadruple therapy for the first-line treatment of Helicobacter pylori infection, with both yielding excellent eradication rates, as shown in a recent trial.

Researchers conducted a multicentre superiority‐design trial, which randomly assigned 382 patients with H. pylori infection to (a) susceptibility‐guided therapies containing esomeprazole 20 mg and amoxicillin 1 g twice daily plus clarithromycin 500 mg, metronidazole 400 mg twice daily, or levofloxacin 500 mg daily for susceptible infections or bismuth 220 mg twice daily and metronidazole 400 mg four times daily for triple‐resistant infections; or to (b) empiric therapy containing esomeprazole 20 mg, bismuth 220 mg twice daily, amoxicillin 1 g and metronidazole 400 mg thrice daily.

Rates of H. pylori eradication were high and similar in the susceptibility‐guided and the empiric regimens (per-protocol rates: 97.7 percent vs 97.6 percent; p=1.00; intent‐to‐treat rates: 91.6 percent vs 85.4 percent; p=0.12).

Overall, susceptibility‐guided therapy was not superior to empiric therapy, with a difference of 0.1 percent in per‐protocol rate and 6.2 percent in intent‐to‐treat rate. Furthermore, both treatment approaches had high adherence and were associated with low adverse event rates.

In light of the findings, researchers pointed out that choosing between the two approaches would depend on availability of susceptibility testing and/or a locally highly effective empiric therapy.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 04 Sep 2019
Use of sodium glucose cotransporter 2 (SGLT2), as compared with dipeptidyl peptidase 4 (DPP4), inhibitors appears to reduce the risk of heart failure and any-cause death without major cardiovascular events in the primary intention-to-treat analysis, according to a study.
Pearl Toh, 04 Sep 2019
More intensive LDL-lowering by adding ezetimibe to simvastatin in elderly individuals aged ≥75 years significantly reduced recurrent cardiovascular (CV) events without raising safety issues compared with simvastatin alone, a secondary analysis of the IMPROVE-IT* has shown.
27 Aug 2019
A once-weekly regimen of 25 mg trelagliptin is effective and safe for type 2 diabetes mellitus (T2DM) patients with severe renal impairment or end-stage renal disease, reports a new study.
Elvira Manzano, 2 days ago

The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.